Pfizer Inc. (PFE) said that Trumenba (Meningococcal Group B Vaccine) received Breakthrough Therapy designation from the U.S. Food and Drug Administration or FDA for active immunization to prevent invasive disease caused by Neisseria meningitidis group B (MenB) in children aged 1 through 9 years.
from RTT - Biotech https://ift.tt/2JiA3ql
via IFTTT
No comments:
Post a Comment